Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)

Zeuschner P., Hölters S., Stöckle M., Seliger B., Mueller A., Bachmann H. S., Grünwald V., Christoph D.C., Stenzl A., Grimm M.-O., Brüning F., Goebell P. J., Augustin M., Roos F., Harde J., Benz-Rüd I., Staehler M., Junker K.

Abstract

pdf-Version

Indikation: Nierenzellkarzinom, Renal Cell Carcinoma / Veranstaltung: - / Journal: Cancers
MARC-2
2021
Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.

Staehler, M., Stöckle, M., Christoph, D. C., Stenzl, A., Potthoff, K., Grimm, M.-O., Klein, D., Harde, J., Brüning, F., Goebell, P. J., Augustin, M., Roos, F., Benz-Rüd, I., Marschner, N., Grünwald, V., 2020

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: / Journal: International Journal of Cancer
MARC-2
2021
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients

Metz, M., Semsek, D., Rogmans, G., Hutzschenreuter, U., Fietz, T., Harde, J., Zacharias, S., Hielscher, C., Lorenz, A., Zahn, M.-O., Guth, D., Liebers, S., Berghorn, M., Grebhardt, S., Matillon, C. D., Egerer, G., Potthoff, K., 2021.

Abstract

pdf

Indikation: Breast Cancer, Mammakarzinom, Non-Hodgkin-Lymphom, Non-Hodgkin-Lymphoma / Veranstaltung: / Journal: Supportive Care in Cancer
CONVENIENCE
2021
Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms

Knauf, W., Abenhardt, W., Koenigsmann, M., Maintz, C., Sandner, R., Zahn, M.-O., Schnell, R., Tech, S., Kaiser-Osterhues, A., Houet, L., Marschner, N., the TLN-Group (Tumour Registry Lymphatic Neoplasms), 2021.

Abstract

Indikation: Lymphatic Neoplasia, Lymphatische Neoplasien / Veranstaltung: / Journal: Hematological Oncology
TLNext
2021
Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry.

Borchert, K; Jacob, C; Wetzel, N; Jänicke, M; Eggers, E; Sauer, A; Marschner, N; Altevers, J; Mittendorf, T; Greiner, W, 2020.

Health Econ Rev 10, 40 (2020). https://doi.org/10.1186/s13561-020-00297-6

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Health Economics Review
TKK
2020
Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Zahn, M.-O., Maintz, C., Bernhardt, C., Losem, C., Stenzinger, A., Heukamp, L.C., Büttner, R., Marschner, N., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Heilmann, M., Sadjadian, P., Gleiber, W., Grah, C., Waller, C.F., Reck, M., Rittmeyer, A., Christopoulos, P., Sebastian, M., Thomas, M., the CRISP Registry Group, 2020.

Lung Cancer. https://doi.org/10.1016/j.lungcan.2020.10.012

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: Lung Cancer
CRISP
2020
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.

Welt, A., Wiesweg, M., Theurer, S., Abenhardt, W., Groschek, M., Müller, L., Schröder, J., Tewes, M., Chiabudini, M., Potthoff, K., Bankfalvi, A., Marschner, N., Schuler, M., Breitenbücher, F., 2020.

Cancer Med 9, 4527-4539. https://doi.org/10.1002/cam4.3092

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Cancer Medicine
PIKTAM
2020
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).

Schimanski, C.C., Kasper, S., Hegewisch-Becker, S., Schröder, J., Overkamp, F., Kullmann, F., Bechstein, W.O., Vöhringer, M., Öllinger, R., Lordick, F., Heinemann, V., Geißler, M., Schulz-Abelius, A., Bernhard, H., Schön, M.R., Greil, R., Galle, P., Lang, H., Schmidtmann, I., Moehler, M., 2020.

Oncoimmunology 9, 1806680.

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Oncoimmunology
LICC
2020
Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial

Staehler M, Stöckle M, Christoph D C, Stenzl A, Potthoff K, Grimm M O, Klein D, Harde J, Brüning F, Goebell P J, Augustin M, Roos F, Benz-Rüd I, Marschner N, Grünwald V, 2020

Int J Cancer, 2020

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: International Journal of Cancer
MARC-2
2020
First results from INFINITY – A Registry on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology in Routine Clinical Practice

U Martens, M Reiser, S Schirrmacher-Memmel, L Sellmann, T Decker, A Schneeweiss, M Schuler, F Bengsch, C Vannier, K Potthoff, N Marschner, B Kasenda, 2020

Oncol Res Treat. 2020;43(suppl 4)(247):251

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
INFINITY
2020